Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People whose general health and ability to carry out daily activities is rated at a good level (ECOG score of 0 or 1), and has been stable for at least 7 days.
• People who have been diagnosed through a tissue biopsy with stomach cancer or cancer at the junction of the stomach and oesophagus (gastroesophageal junction) that has either spread to other parts of the body or cannot be surgically removed.
• People who have already received one round of chemotherapy for this cancer and whose cancer has continued to grow, or people whose cancer came back or got worse within 6 months of finishing adjuvant (preventative) chemotherapy.
• People who have at least one measurable area of cancer that meets specific measurement standards used in clinical trials (RECIST 1.1).
• People whose blood counts and organ function meet the required levels, including haemoglobin, white blood cells, platelets, liver enzymes, bilirubin, kidney function, and urine protein levels (confirm specific values with the trial site).
• People with normal blood clotting function and no active bleeding.
• Women who could become pregnant must have a negative pregnancy test within 14 days before joining, and must agree to use reliable contraception during the trial and for 8 weeks after the last dose; men must either have had a surgical procedure to prevent fathering children or agree to use reliable contraception during the trial and for 8 weeks after the last dose.
• People with an expected survival of at least 3 months.
• People who are willing to participate and have signed a consent form agreeing to take part.
• People who are expected to be able to attend follow-up appointments and comply with the study requirements.

Who may not be able to join:

• People who have previously been treated with a type of drug called a VEGFR inhibitor.
• People who have previously received paclitaxel (a chemotherapy drug) — except those who received it as part of pre- or post-surgery treatment, where that treatment ended more than 6 months before their cancer progressed.
• People who have received a live vaccine within 4 weeks before joining, or who may need one during the study.
• People who have an active autoimmune disease, or who have had one within the 4 weeks before joining.
• People who have previously had a bone marrow transplant or organ transplant from another person.
• People with high blood pressure that cannot be controlled with medication (systolic pressure of 150 mmHg or higher, and/or diastolic pressure of 90 mmHg or higher).
• People who have a condition that affects how the body absorbs medication, or who are unable to swallow tablets or capsules.
• People with certain active digestive conditions such as stomach or bowel ulcers, inflammatory bowel disease, or tumours at risk of bleeding or causing a hole in the digestive tract.
• People with a significant history of heavy bleeding in the past 3 months, or a stroke or similar blood clot event in the past 12 months.
• People with serious heart conditions, including a heart attack, severe chest pain, or heart bypass surgery within the past 6 months, significant heart failure, certain irregular heart rhythms, or reduced heart pumping function.
• People with a serious active or uncontrolled infection.
• People known to have HIV, active hepatitis B, or active hepatitis C infection (confirm specific testing requirements with the trial site).
• People with any other significant medical condition, abnormal test results, or health issue that the trial doctor believes could make participation unsafe or affect the trial results.
• People whom the trial investigators consider unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.